8-K: Bausch Health to Reaffirm 2025 Guidance at JPM Conference

Bausch Health Companies Inc. announced it will reaffirm its full year 2025 guidance at the higher end of the range during the upcoming J.P. Morgan Healthcare Conference.

Summary

• Bausch Health Companies Inc. will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.
• Management plans to provide an update for investors relating to certain strategic and business matters during the presentation.
• The company expects to reaffirm its full year 2025 guidance at the higher end of the previously provided range for Bausch Health, excluding Bausch + Lomb Corporation.
• This guidance was initially issued in the third quarter 2025 financial results press release dated October 29, 2025.
• A live audio webcast of the event will be accessible on the Investor Relations section of Bausch Health's website, with a replay and presentation copy available afterward.

Sentiment

Score: 7

Explanation: The reaffirmation of guidance at the higher end of the range is a positive signal, indicating management's confidence in the company's performance. However, it's not new guidance, just a reaffirmation, which tempers the enthusiasm slightly.

Positives

• Reaffirming full year 2025 guidance at the higher end of the range for Bausch Health (excluding Bausch + Lomb Corporation) indicates strong performance or confidence in achieving top-tier targets.
• Participation in the J.P. Morgan Healthcare Conference provides a significant platform for investor engagement and strategic updates, enhancing transparency and market visibility.

Risks

• Forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those described, including those discussed in the company's most recent Annual Report on Form 10-K and other SEC filings.

Future Outlook

Management expects to reaffirm its full year 2025 guidance at the higher end of the range for Bausch Health, excluding Bausch + Lomb Corporation, during its presentation at the J.P. Morgan Healthcare Conference.

Management Comments

• Management will provide an update for investors relating to certain strategic and business updates.
• Management also expects to reaffirm the full year 2025 guidance at the higher end of the range for Bausch Health excluding Bausch + Lomb Corporation that it provided in its financial results press release for the third quarter of 2025 dated October 29, 2025.

Industry Context

This announcement positions Bausch Health as actively engaging with the investment community at a major industry conference, signaling confidence in its near-term financial performance, particularly for its core operations excluding the recently spun-off Bausch + Lomb. Reaffirming guidance at the high end suggests a positive outlook compared to peers who might be adjusting expectations downwards in a dynamic healthcare market.

Comparison to Industry Standards

• Reaffirming guidance at the higher end of the range is generally viewed positively, especially in the pharmaceutical and healthcare sectors where companies often face regulatory, competitive, and R&D challenges. This suggests Bausch Health's performance is robust relative to its own prior expectations and potentially outperforming some industry peers who may be struggling to meet targets.
• Many companies, such as Pfizer or Johnson & Johnson, often provide guidance updates at major conferences. Bausch Health's reaffirmation at the high end contrasts with companies that might issue downward revisions due to market pressures or clinical trial setbacks, indicating relative strength.

Stakeholder Impact

• Shareholders: Potential positive impact due to reaffirmed strong guidance, suggesting stable or improving financial performance and increased confidence in the company's outlook.
• Investors: Provides clarity and confidence regarding the company's financial trajectory for 2025, aiding investment decisions.

Next Steps

• Bausch Health management to present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at approximately 3:45 p.m. PT (6:45 p.m. ET).
• A live audio webcast and replay of the presentation will be available on the company's Investor Relations website following the event.

Key Dates

Recommendation

While reaffirming guidance at the higher end is positive, this filing is an update to previously issued guidance rather than new, significantly improved projections. It signals stability and confidence but doesn't introduce new catalysts for a 'buy' recommendation. Investors should hold and await further details from the JPM Conference presentation and subsequent full financial results for a more comprehensive assessment.

Keywords

Bausch Health, J.P. Morgan Healthcare Conference, 2025 Guidance, Financial Outlook, Investor Update, BHC, Pharmaceuticals, Healthcare